4,865 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,865 shares of the medical equipment provider’s stock, valued at approximately $440,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Riverwater Partners LLC boosted its holdings in shares of Lantheus by 102.9% during the fourth quarter. Riverwater Partners LLC now owns 11,182 shares of the medical equipment provider’s stock worth $1,000,000 after purchasing an additional 5,671 shares during the period. Landscape Capital Management L.L.C. grew its holdings in shares of Lantheus by 312.8% during the 4th quarter. Landscape Capital Management L.L.C. now owns 16,358 shares of the medical equipment provider’s stock valued at $1,463,000 after acquiring an additional 12,395 shares in the last quarter. Foundry Partners LLC increased its stake in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 133 shares during the last quarter. Cynosure Group LLC raised its holdings in shares of Lantheus by 9.2% during the fourth quarter. Cynosure Group LLC now owns 3,558 shares of the medical equipment provider’s stock worth $318,000 after acquiring an additional 299 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Lantheus by 37.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 323,900 shares of the medical equipment provider’s stock valued at $28,976,000 after purchasing an additional 87,412 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock valued at $6,110,806 in the last three months. Company insiders own 1.50% of the company’s stock.

Lantheus Trading Up 3.5 %

NASDAQ LNTH opened at $102.00 on Friday. Lantheus Holdings, Inc. has a 1 year low of $59.56 and a 1 year high of $126.89. The company has a fifty day simple moving average of $94.00 and a 200 day simple moving average of $95.62. The company has a market cap of $6.98 billion, a P/E ratio of 16.97 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of several research reports. B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.